• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CA19-9 和 CA242 作为胰腺癌的肿瘤标志物诊断:一项荟萃分析。

CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis.

机构信息

Department of Nuclear Medicine, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Rd., Shanghai, 200040, People's Republic of China.

出版信息

Clin Exp Med. 2014 May;14(2):225-33. doi: 10.1007/s10238-013-0234-9. Epub 2013 Mar 3.

DOI:10.1007/s10238-013-0234-9
PMID:23456571
Abstract

Pancreatic cancer has the worst prognosis of any gastrointestinal cancer, with the mortality approaching the incidence. Early detection is crucial for improving patient prognosis. We therefore performed a meta-analysis to evaluate and compare the sensitivity and specificity of CA19-9 and CA242 in pancreatic cancer. We searched PubMed, EMBASE, and the Cochrane Library for studies that evaluated the diagnostic validity of CA19-9 and CA242 between January 1966 and March 2011. Meta-analysis methods were used to pool sensitivity and specificity and to construct a summary receiver-operating characteristic (SROC) curve. A total of 11 studies that included 2,316 patients who fulfilled all of the inclusion criteria were considered for analysis. The pooled sensitivities for CA242 and CA19-9 were 0.719 (95 % confidence interval [CI] 0.690-0.746) and 0.803 (95 % CI 0.777-0.826), respectively. The pooled specificities of CA242 and CA19-9 were 0.868 (95 % CI 0.849-0.885) and 0.802 (95 % CI 0.780-0.823), respectively. The diagnostic odds ratio (DOR) estimate was significantly higher for CA242 (16.261) than for CA19-9 (15.637). Our meta-analysis showed that CA242 and CA19-9 could play different roles in the diagnosis of pancreatic cancer. Although the sensitivity of CA242 is lower than that of CA19-9, its specificity is greater.

摘要

胰腺癌是所有胃肠道癌中预后最差的,死亡率接近发病率。早期发现对于改善患者预后至关重要。因此,我们进行了一项荟萃分析,以评估和比较 CA19-9 和 CA242 在胰腺癌中的敏感性和特异性。我们检索了 PubMed、EMBASE 和 Cochrane 图书馆,以评估 1966 年 1 月至 2011 年 3 月期间 CA19-9 和 CA242 的诊断有效性的研究。采用荟萃分析方法汇总敏感性和特异性,并构建综合受试者工作特征(SROC)曲线。共有 11 项研究符合所有纳入标准,共纳入 2316 例患者进行分析。CA242 和 CA19-9 的合并敏感性分别为 0.719(95%置信区间 0.690-0.746)和 0.803(95%置信区间 0.777-0.826)。CA242 和 CA19-9 的合并特异性分别为 0.868(95%置信区间 0.849-0.885)和 0.802(95%置信区间 0.780-0.823)。CA242 的诊断比值比(DOR)估计值明显高于 CA19-9(16.261 对 15.637)。我们的荟萃分析表明,CA242 和 CA19-9 在胰腺癌的诊断中可能发挥不同的作用。尽管 CA242 的敏感性低于 CA19-9,但特异性更高。

相似文献

1
CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis.CA19-9 和 CA242 作为胰腺癌的肿瘤标志物诊断:一项荟萃分析。
Clin Exp Med. 2014 May;14(2):225-33. doi: 10.1007/s10238-013-0234-9. Epub 2013 Mar 3.
2
Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis.肿瘤标志物CA19-9、CA242和CEA在胰腺癌诊断中的Meta分析
Int J Clin Exp Med. 2015 Jul 15;8(7):11683-91. eCollection 2015.
3
Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.血清CA19-9、CEA、CA125和CA242在同步放化疗治疗的胰腺癌患者诊断及预后中的应用价值
Asian Pac J Cancer Prev. 2015;16(15):6569-73. doi: 10.7314/apjcp.2015.16.15.6569.
4
Serum carbohydrate antigen 242 expression exerts crucial function in the diagnosis of pancreatic cancer.血清糖类抗原242表达在胰腺癌诊断中发挥关键作用。
Tumour Biol. 2014 Jun;35(6):5281-6. doi: 10.1007/s13277-014-1687-5. Epub 2014 Feb 9.
5
Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.骨桥蛋白和 CA242 作为潜在的诊断血清生物标志物,与 CA19.9 联合检测可提高胰腺癌的检出率。
Cancer Sci. 2018 Sep;109(9):2841-2851. doi: 10.1111/cas.13712. Epub 2018 Jul 24.
6
Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer.肿瘤标志物CA19.9、CA195、CAM43、CA242和TPS在胰腺癌诊断及随访中的表现
Clin Chem. 1993 Mar;39(3):420-3.
7
Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.CA242与CA19-9用于胰腺癌诊断的比较研究
Br J Cancer. 1994 Sep;70(3):481-6. doi: 10.1038/bjc.1994.331.
8
The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.血清癌胚抗原(CEA)、糖类抗原19-9(CA19-9)和糖类抗原242(CA242)在胰腺癌诊断及预后中的临床价值
Eur J Surg Oncol. 2005 Mar;31(2):164-9. doi: 10.1016/j.ejso.2004.09.007.
9
Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer.胰腺癌患者血清中肿瘤特异性生长因子(TSGF)、糖类抗原242(CA242)和糖类抗原19-9(CA19-9)的水平。
World J Gastroenterol. 2004 Jun 1;10(11):1675-7. doi: 10.3748/wjg.v10.i11.1675.
10
Carbohydrate antigen 242 highly consists with carbohydrate antigen 19-9 in diagnosis and prognosis of colorectal cancer: study on 185 cases.糖链抗原 242 在结直肠癌的诊断和预后中与糖链抗原 19-9 高度一致:185 例研究。
Med Oncol. 2012 Jun;29(2):1030-6. doi: 10.1007/s12032-011-9967-z. Epub 2011 May 7.

引用本文的文献

1
Harnessing artificial intelligence for detection of pancreatic cancer: a machine learning approach.利用人工智能检测胰腺癌:一种机器学习方法。
Clin Exp Med. 2025 Jul 1;25(1):228. doi: 10.1007/s10238-025-01761-5.
2
Metagenomic Microbial Signatures for Noninvasive Detection of Pancreatic Cancer.用于胰腺癌无创检测的宏基因组微生物特征
Biomedicines. 2025 Apr 21;13(4):1000. doi: 10.3390/biomedicines13041000.
3
Structure-Based Mechanism and Specificity of Human Galactosyltransferase β3GalT5.基于结构的人类半乳糖基转移酶β3GalT5的作用机制及特异性

本文引用的文献

1
Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.癌抗原 19-9 是接受含吉西他滨化疗的晚期胰腺癌患者的预后和预测生物标志物:6 项前瞻性研究的汇总分析。
Cancer. 2013 Jan 15;119(2):285-92. doi: 10.1002/cncr.27734. Epub 2012 Jul 11.
2
Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer.胰腺癌的诊断、预后和预测生物标志物。
J Surg Oncol. 2013 Jan;107(1):15-22. doi: 10.1002/jso.23192. Epub 2012 Jun 21.
3
Pancreatic cancer stem cell biology and its therapeutic implications.
J Am Chem Soc. 2025 Apr 2;147(13):10875-10885. doi: 10.1021/jacs.4c11724. Epub 2025 Mar 25.
4
The road to overcome pancreatic cancer: Where are we?攻克胰腺癌之路:我们进展到哪一步了?
Heliyon. 2024 Sep 19;10(19):e38196. doi: 10.1016/j.heliyon.2024.e38196. eCollection 2024 Oct 15.
5
Significant elevation of serum CA19-9 and CA242 levels induced by dulaglutide.度拉糖肽引起血清 CA19-9 和 CA242 水平显著升高。
BMJ Case Rep. 2024 May 6;17(5):e257657. doi: 10.1136/bcr-2023-257657.
6
Heterogeneous changes in gut and tumor microbiota in patients with pancreatic cancer: insights from clinical evidence.胰腺癌患者肠道和肿瘤微生物组的异质性变化:来自临床证据的见解。
BMC Cancer. 2024 Apr 15;24(1):478. doi: 10.1186/s12885-024-12202-z.
7
Integrating a microRNA signature as a liquid biopsy-based tool for the early diagnosis and prediction of potential therapeutic targets in pancreatic cancer.整合 microRNA 特征作为一种基于液体活检的工具,用于胰腺癌的早期诊断和潜在治疗靶点预测。
Br J Cancer. 2024 Jan;130(1):125-134. doi: 10.1038/s41416-023-02488-4. Epub 2023 Nov 10.
8
Combined analytical approach empowers precise spectroscopic interpretation of subcellular components of pancreatic cancer cells.联合分析方法使精确解析胰腺癌亚细胞成分的光谱成为可能。
Anal Bioanal Chem. 2023 Dec;415(29-30):7281-7295. doi: 10.1007/s00216-023-04997-w. Epub 2023 Oct 31.
9
PiRNA Obtained through Liquid Biopsy as a Possible Cancer Biomarker.通过液体活检获得的PiRNA作为一种潜在的癌症生物标志物。
Diagnostics (Basel). 2023 May 29;13(11):1895. doi: 10.3390/diagnostics13111895.
10
Vibrational spectroscopy - are we close to finding a solution for early pancreatic cancer diagnosis?振动光谱学——我们是否即将找到早期胰腺癌诊断的解决方案?
World J Gastroenterol. 2023 Jan 7;29(1):96-109. doi: 10.3748/wjg.v29.i1.96.
胰腺癌干细胞生物学及其治疗意义。
J Gastroenterol. 2011 Dec;46(12):1345-52. doi: 10.1007/s00535-011-0494-7. Epub 2011 Nov 3.
4
Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview.血清生物标志物用于提高胰腺癌的诊断:当前概述。
J Cancer Res Clin Oncol. 2011 Mar;137(3):375-89. doi: 10.1007/s00432-010-0965-x. Epub 2010 Dec 31.
5
Epidemiology of pancreatic cancer: an update.胰腺癌的流行病学:最新进展。
Dig Dis. 2010;28(4-5):645-56. doi: 10.1159/000320068. Epub 2010 Nov 18.
6
Molecular and clinical markers of pancreas cancer.胰腺癌的分子和临床标志物
JOP. 2010 Nov 9;11(6):536-44.
7
Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease.胰腺癌切除术后 CA19-9 未能恢复正常,相当于发生了转移。
Ann Surg Oncol. 2011 Apr;18(4):1116-21. doi: 10.1245/s10434-010-1397-1. Epub 2010 Nov 2.
8
Current status of molecular markers for early detection of sporadic pancreatic cancer.散发性胰腺癌早期检测分子标志物的现状
Biochim Biophys Acta. 2011 Jan;1815(1):44-64. doi: 10.1016/j.bbcan.2010.09.002. Epub 2010 Oct 1.
9
Advances in pancreatic cancer detection.胰腺癌检测的新进展。
Adv Clin Chem. 2010;51:145-80. doi: 10.1016/s0065-2423(10)51006-0.
10
Imaging techniques in pancreatic tumors.胰腺肿瘤的影像学技术。
Expert Rev Med Devices. 2010 Mar;7(2):257-73. doi: 10.1586/erd.09.67.